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Abstract 
This study aims to observe the spectrum of Prenatal 
Diagnosis of Rare Genetic conditions at a Tertiary care 
hospital in Karachi. This is a retrospective review 
conducted at the Aga Khan University Hospital, Karachi 
from January 2016 to July 2018. All cases undergoing 
invasive testing by Chorionic villus sampling for 
indications other than Thalassemia were included. Forty 
percent of patients in our cohort underwent invasive 
testing for muscular dystrophies particularly survival 
motor neuron (SMN) gene deletion and 32% for Cystic 
Fibrosis. Other rare disorders like JAM 3 mutation, PEX 1 
gene, Barters Syndrome, Wardenberg, Bardet-Beidl 
Syndrome and Lissencephaly accounted for 28%. 
Sophistication in laboratory technology and DNA 
banking has improved the prenatal diagnosis of rare 
genetic disorders particularly SMN gene deletion. 
Integrated care involving foetal medicine specialist, 
Paediatric geneticist, and dedicated Laboratory 
personnel improves Counseling and Diagnosis of rare 
genetic conditions. Provision of dedicated nursing staff 
along with strengthening of welfare facility for non-
affording patients would improve the uptake of invasive 
testing.  
Keywords: CVS (chorionic villous sampling, SMN (Survival 
motor neuron), SMA (spinal muscular atrophy). 
https://doi.org/10.5455/JPMA.11601 
Introduction 
Chromosomal abnormalities and genetic disorders are 
among the important causes of perinatal morbidity and 
mortality.1 The prevalence of genetic disorders has been 
increasing worldwide.1 It is even more common in the 
under developed countries like Pakistan primarily due to 
consanguinity and high birth rate.2 Consanguinity 
accounts for 61.3 per cent of cases being more common 
in rural than urban setting.3 
Thalassemia is the leading single gene defect followed by 
Cystic fibrosis.4 Globally, there are 80 million carriers of β-
thalassemia. Around 5000-9000 children are born each 
year with β-thalassemia in Pakistan (9.8 million carriers in 
the total population).5 The frequency of delta F508 del in 
cystic fibrosis patients is 60% in Pakistan.6 
Other genetic disorders include survival motor neuron 
(SMN) gene deletion and Duchene and Spinal muscular 
dystrophies. SMN is an autosomal recessive 
neurodegenerative disorder in which there is progressive 
degeneration of alpha motor neurons leading to muscle 
atrophy and paralysis.7-9 The exact prevalence of SMN 
gene in our population is still not known but is seen in 
relatively high numbers in the Genetics and Foetal 
Medicine clinics.  
Prenatal diagnosis of Genetic disorders is made by 
invasive testing with Chorionic villous sampling 
(CVS).10 The procedure is commonly used for the 
diagnosis of Thalassemia and Cystic Fibrosis. More 
recently this procedure is being used for rare genetic 
disorders in particular SMN deletion. In addition the 
Laboratory is providing the service of DNA banking. 
CVS is a preferred method as the amount of DNA 
extracted is more as compared to Amniocentesis.11,12 It 
has a miscarriage rate comparable to amniocentesis in 
expert hands.13,14 
This study describes the spectrum of rare genetic 
disorders and their diagnosis at our Foetal Medicine unit 
in collaboration with Paediatric Geneticist and 
Laboratory. The findings will be helpful in future 
counseling of patients and streamline referrals. 
Methods 
This is a retrospective review conducted at the Aga Khan 
University Hospital, Karachi, Pakistan from 1st January 
2016 to 31st July 2018. We included all cases undergoing 
invasive testing by CVS for genetic conditions other than 
Thalassemia. A prior Ethical Review Committee approval 
was obtained. 
The Aga Khan University is a private sector tertiary 
referral hospital in Karachi and carries out more than 
5800 deliveries annually. A third of these are high-risk 
pregnancies. The University has four secondary care 
hospitals with 15000 deliveries annually. The 
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Obstetric department is backed up with a well-
equipped state of the art 24 bedded Neonatal 
Intensive Care Unit (NICU). 
Foetal medicine unit at the Aga Khan University caters for 
all high risk pregnancies. The unit is one of the first 
centers in Pakistan. More than 4000 ultrasound scans are 
performed annually. Apart from inter and intra-
departmental referrals the unit receives patients from all 
over the country and some of the neighbouring countries 
like UAE and Afghanistan. The services provided include 
first trimester screening, genetic sonography, invasive 
testing and genetic counseling.  
In the recent years the Chorionic Villus sampling has been 
made available for the diagnosis of genetic conditions 
other than Thalassemia. This is mainly due to the 
availability of DNA banking at our hospital. The procedure 
of CVS is preferably performed from 12 weeks of gestation 
onwards 
Data was collected on pre-structured questionnaire from 
hospital medical records. Data were entered and analyzed 
by SPSS v. 20.0. Descriptive analysis was done and 
frequencies were calculated for different indications of 
CVS and their outcomes. 
Results 
In the last two years, there were 25 procedures for other 
genetic disorders. Details are given in Table-1. 
Ten (40%) cases were performed for muscular dystrophies 
particularly spinal muscular atrophy (SMN gene deletion 
32%). Details of results of other genetic disorders is given 
in Table-2.  
Outcomes of the cases are described in Table-3. There 
were total 17 (68%) cases for whom outcome could 
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Table-1: Indications for Chorionic Villus Sampling. 
 
Indication of CVS                                                                                 Total procedures done 
 
Cystic Fibrosis                                                                                                              8 (32%) 
Muscular dystrophies                                                                                              10(40%) 
SMN Gene                                                                                                                     8(32%) 
Muscular dystrophy                                                                                                   2 (8%) 
Other genetic disorders                                                                                           7 (28%) 
  u JAM 3 mutation                                                                                                    1 
  u PEX 1 gene                                                                                                             1 
  u PW 569 gene (Nemaline Myopathy)                                                             1 
  u Lissencephaly                                                                                                        1 
  u Barters Syndrome                                                                                                1 
  u Wardenberg syndrome                                                                                      1 
  u Bardet-Beidl Syndrome                                                                                     1 
Total procedures for genetic disorders other than thalessemia                      25
Table-2: CVS results for different indications other than thalassemia. 
 
Indication for CVS                                                                        Heterozygous                                           Homozygous                                                 Normal                                               Inconclusive 
 
Cystic Fibrosis                                                                                             6 (75%)                                                                                                                                 2(25%)                                                               
SMN gene                                                                                                    4 (50%)                                                        1(12.5%)                                                       2 (25%)                                                    1(12.5%) 
Muscular dystrophy                                                                                        -                                                                                                                                       2 (100%)                                                             
Other genetic disorders                                                                                                                                                                                                                                                                                                        
  u JAM 3 mutation                                                                                   1                                                                                                                                              -                                                                     
  u PEX 1 gene                                                                                            -                                                                                                                                              1                                                                     
  u PW 569 gene (Nemaline Myopathy)                                            -                                                                                                                                              1                                                                     
  u Barters Syndrome                                                                               -                                                                                                                                              1                                                                     
  u Wardenberg syndrome                                                                     -                                                                                                                                              1                                                                     
  u Bardet-biedel syndrome                                                                  1                                                                                                                                                                                                                     
  u Lissencephaly                                                                                                                                                                1                                                                                                                                            
Table-3: Outcome of CVS cases. 
 
                                                                Livebirth                       Miscarriage                         TOP                              IUD                         NND                  Lost to follow up            Ongoing pregnancies 
                                                                    n (%)                                  n (%)                              n (%)                          n (%)                      n (%)                              n (%)                                          n (%) 
 
Cystic Fibrosis                                                -                                             -                                        -                                     -                                -                               5 (62.5%)                                   3 (37.5%) 
SMN gene                                                2 (25%)                             1 (100%)                        1 (100%)                                                              -                               1 (12.5%)                                   3 (37.5%) 
Muscular dystrophy                            1(12.5%)                                    -                                                                               -                                -                               1 (12.5%)                                            - 
Other genetic disorders                     4(62.5%)                                    -                                        -                                     -                                -                               1 (12.5%)                                     2(25%) 
Total                                                          7(28%)                                 1(4%)                              1(4%)                               0                                0                                 8(32%)                                       8(32%) 
 
TOP: Termination of Pregnancy. IUD: Intrauterine Death. NND: Neonatal Death, SMN: Survival Motor Neuron.
not be determined among which 9 (36%) are with 
ongoing pregnancies and 8 (32%) cases were lost to 
follow up as they were only referred to the tertiary 
care for prenatal diagnosis. 
Discussion 
Genetic disorders are emerging as the important causes 
of perinatal morbidity and morbidity.1 Worldwide the 
prevalence of single gene disorders is 10/1000 births 
(WHO 2013). The most common being thalassemia 
followed by cystic fibrosis.4 
SMN gene deletion is among the less commonly 
diagnosed disorder. The global prevalence of which is 
around 1-2 per 100,000.8 The carrier frequency of SMN is 1 
in 35 to 1 in 50 in the general population.15,16 A higher 
prevalence of SMA has been reported in Iran, Saudi 
Arabia, Egypt and Pakistan. This could largely be 
attributed to the higher rate of Consanguinity.8.17 In a 
another series consanguinity in Pakistan was as high as 
68% in babies with SMN gene deletions.8 Though the 
exact prevalence of this condition in Pakistan remains 
unknown, in our study 32% of the CVS were done for SMN 
deletions.  
Invasive testing for aneuploidy has been available since 
the inception of the Foetal Medicine services at the 
University. In the last couple of years the spectrum of 
prenatal diagnostic facility has expanded with the 
introduction of SMN and DMD gene testing locally. 
Foetomaternal section is a dedicated department to 
provide monitoring and prenatal diagnosis in our unit. 
This unit offers first trimester screening, Genetic 
Sonogram and monitoring of all high risk women with 
Doppler scan, ultrasound and Preterm delivery screening. 
Counseling remains a vital part of management of high 
risk pregnancy. In addition to foetal medicine specialist, 
we have Paediatric geneticist and counseling services. As 
prenatal diagnosis is now becoming better, clinicians 
have to counsel the parents with certain disorders. 
Counseling remains a challenge in the absence of the 
region-specific data. 
Improvement in laboratory techniques along with the 
foetal medicine services have largely contributed to 
improved outcome of pregnancies with poor pregnancy 
outcome. In the last 18 months, DNA banking has also 
been started in Aga Khan University. It allows 
conservation of genetic material and significant amount 
of DNA for multiple testing of an individual in future.18-20 
Our study clearly indicates that collaboration with 
reference laboratories and improvement in DNA 
extraction can broaden the scope of work. As this 
improves, the number of patients with undetermined 
cause of poor pregnancy outcome would decline. 
Provision of new diagnostic tests obviously warrants an 
improvement in the provision of welfare to deserving and 
non-affording patients. Our unit is working closely with 
the welfare department to facilitate and help the needy 
patients. A large number of patients accessing our facility 
belong to middle /low income strata. 
One of the limitations of our study is that the lost to 
follow up was around 32%. This can be explained by the 
fact that vast majority of referrals for Prenatal Diagnosis 
are from outside Karachi. In addition, there is no 
dedicated nursing staff to collect the follow up. Trained 
nurses can play a role in counseling and data keeping in 
such cases. 
Conclusion 
Prenatal diagnosis for genetic disorders other than 
Thalassemia has been made available. This is primarily 
due the facility of DNA banking. This has led to testing 
other disorders particularly SMN gene deletion locally. 
Multidisciplinary input with Genetic Counseling, 
dedicated specialty personnel and external linkages have 
improved the scope of this work. Provision of welfare 
would benefit greater number of patients. 
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